# A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

> **NCT05573802** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hellenic Society of Hematology** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma
- Neoplasms
- Neoplasm, Plasma Cell
- Gammopathy, Monoclonal
- Paraproteinemias
- Blood Protein Disorders
- Haematologic Disease
- Corneal Disease

## Interventions

- **DRUG:** Belantamab Mafodotin-Blmf
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Nirogacestat

## Key facts

- **NCT ID:** NCT05573802
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05573802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05573802, "A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05573802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*